{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T04:46:05Z","timestamp":1782794765751,"version":"3.54.5"},"reference-count":22,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T00:00:00Z","timestamp":1782777600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"abstract":"<jats:p>\n                    Latent autoimmune diabetes in youth (LADY) is a poorly characterized form of autoimmune diabetes with onset between 8 and 29 years of age and with slow progression toward insulin dependence, similarly to latent autoimmune diabetes of the adult (LADA), which leads to diagnostic difficulties and possibly to therapeutic implications. In this case series, we discuss two cases of juvenile- and young adult-onset autoimmune diabetes with very low insulin need at least after diagnosis and the efficacy of treatment with semaglutide. In case 1, a 20-year-old woman with obesity (31.8 kg\/m\n                    <jats:sup>2<\/jats:sup>\n                    ) with a non-ketoacidotic onset of diabetes was initially put on metformin and basal insulin. Previous ultrasound of the abdomen showed a hyperechogenic liver pattern. Tests showed high-titer multiple diabetes-related autoantibodies positivity, but still detectable C-peptide levels; thus, metformin was stopped and semaglutide was started. After 12 months, the patient still continues oral semaglutide and basal insulin, with detectable C-peptide, and has experienced significant weight loss (\u221220 kg) and resolution of liver steatosis. In case 2, a 13-year-old girl was diagnosed with autoimmune diabetes, with tests showing high-titer multiple diabetes-related autoantibodies positivity. She was initially put on multiple daily insulin injections (MDI). After almost 2 years, presenting to our care with still detectable C-peptide, we decided to stop meal-time insulin and to start oral semaglutide. After 15 months of follow-up on the latter treatment, the patient presents optimal glycemic control and increased C-peptide levels. This is the first case series that shows the possibility of treating LADY with oral semaglutide and basal insulin with optimal glycometabolic outcomes. Moreover, semaglutide treatment also had beneficial effects on weight control and non-confirmed effects on metabolic dysfunction-associated steatotic liver disease (MASLD).\n                  <\/jats:p>","DOI":"10.3389\/fendo.2026.1833794","type":"journal-article","created":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T04:24:03Z","timestamp":1782793443000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Case Report: Latent autoimmune diabetes in two young female patients successfully treated with oral semaglutide and basal insulin"],"prefix":"10.3389","volume":"17","author":[{"given":"Maria Elena","family":"Lunati","sequence":"first","affiliation":[{"name":"Division of Endocrinology, ASST Fatebenefratelli-Sacco","place":["Milan, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Galesi","sequence":"additional","affiliation":[{"name":"Division of Endocrinology, ASST Fatebenefratelli-Sacco","place":["Milan, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Davide","family":"Bernasconi","sequence":"additional","affiliation":[{"name":"Division of Endocrinology, ASST Fatebenefratelli-Sacco","place":["Milan, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Camilla","family":"Tinari","sequence":"additional","affiliation":[{"name":"Division of Endocrinology, ASST Fatebenefratelli-Sacco","place":["Milan, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Fiorina","sequence":"additional","affiliation":[{"name":"Division of Endocrinology, ASST Fatebenefratelli-Sacco","place":["Milan, Italy"]},{"name":"Department of Biomedical and Clinical Sciences, University of Milan","place":["Milan, Italy"]},{"name":"International Center for T1D, Pediatric Clinical Research Center Romeo ed Enrica Invernizzi, DIBIC, Universit\u00e0 di Milano","place":["Milan, Italy"]},{"name":"Nephrology Division, Boston Children\u2019s Hospital, Harvard Medical School","place":["Boston, MA, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,6,30]]},"reference":[{"key":"B1","unstructured":"Classification of diabetes mellitus 2019 classification of diabetes mellitus\n          \n          2019"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1691377","article-title":"Latent autoimmune diabetes in youth","volume":"16","author":"Sun","year":"2025","journal-title":"Front Immunol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.2337\/dbi20-0017","article-title":"Management of latent autoimmune diabetes in adults: A consensus statement from an international expert panel","volume":"69","author":"Buzzetti","year":"2020","journal-title":"Diabetes"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1111\/pedi.13450","article-title":"Clinical characteristics and cardiovascular risk profile in children and adolescents with latent autoimmune diabetes: Results from the German\/Austrian prospective diabetes follow-up registry","volume":"23","author":"Welters","year":"2022","journal-title":"Pediatr Diabetes"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.2337\/dc12-0931","article-title":"Adult-onset autoimmune diabetes in Europe is prevalent with a broad clinical phenotype: Action LADA 7","volume":"36","author":"Hawa","year":"2013","journal-title":"Diabetes Care"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/j.pcd.2020.07.008","article-title":"Prevalence of diabetes-associated autoantibodies among patients presenting with type 2 diabetes and related metabolic differences","volume":"15","author":"Moosaie","year":"2021","journal-title":"Prim Care Diabetes"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-012-2463-y","article-title":"Time dynamics of autoantibodies are coupled to phenotypes and add to the heterogeneity of autoimmune diabetes in adults: The HUNT study, Norway","volume":"55","author":"S\u00f8rgjerd","year":"2012","journal-title":"Diabetologia"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.2337\/db21-675-p","article-title":"675-P: Effects of liraglutide in T1D by baseline anthropometrics in ADJUNCT One and Two","volume":"23","author":"Dejgaard","year":"2021","journal-title":"Diabetes"},{"key":"B9","doi-asserted-by":"publisher","first-page":"720","DOI":"10.2337\/dc25-2249","article-title":"Effect of semaglutide on insulin dose reduction in adults with type 1 diabetes and obesity using automated insulin delivery systems: ADJUST-T1D post hoc analysis","volume":"49","author":"Karakus","year":"2025","journal-title":"Diabetes Care"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1155\/2014\/851378","article-title":"Characteristics and determinants of partial remission in children with type 1 diabetes using the insulin-dose-adjusted A1c definition","volume":"2014","author":"Pecheur","year":"2014","journal-title":"J Diabetes Res"},{"key":"B11","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1159\/000543169","article-title":"International Society for Pediatric and Adolescent Diabetes Clinical Practice Consensus Guidelines 2024: Insulin and adjunctive treatments in children and adolescents with diabetes","volume":"97","author":"Cengiz","year":"2025","journal-title":"Horm Res Paediatr"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-024-01931-z","article-title":"Glucagon-like peptide-1 receptor: mechanisms and advances in therapy","volume":"9","author":"Zheng","year":"2024","journal-title":"Signal Transd Targ Ther"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1111\/dom.13237","article-title":"Dulaglutide treatment results in effective glycaemic control in latent autoimmune diabetes in adults (LADA): A post-hoc analysis of the AWARD-2, -4 and -5 Trials","volume":"20","author":"Pozzilli","year":"2018","journal-title":"Diabetes Obes Metab"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1056\/EVIDoa2500173","article-title":"Semaglutide in adults with type 1 diabetes and obesity","volume":"4","author":"Shah","year":"2025","journal-title":"NEJM Evid"},{"key":"B15","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1210\/clinem\/dgag072","article-title":"The use of semaglutide as an add-on therapy in patients with latent autoimmune diabetes in adults","author":"Lunati","year":"2026","journal-title":"J Clin Endocrinol Metab"},{"key":"B16","unstructured":"Rybelsus (Semaglutide) [Summary of product characteristics]\n          \n          2024"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.4274\/jcrpe.galenos.2024.2024-1-5","article-title":"Efficacy of glucagon-like peptide-1 receptor agonists in overweight\/obese and\/or T2DM adolescents: A meta-analysis based on randomized controlled trials","volume":"16","author":"Dai","year":"2024","journal-title":"JCRPE J Clin Res Pediatr Endocrinol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa2413258","article-title":"Phase 3 trial of semaglutide in metabolic dysfunction\u2013associated steatohepatitis","volume":"392","author":"Sanyal","year":"2025","journal-title":"N Engl J Med"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1177\/15209156251362497","article-title":"Real-world evidence of the effect of adjunctive semaglutide on weight change, glycemic control, and metabolic dysfunction-associated steatotic liver disease in people with type 1 diabetes","volume":"28","author":"Mertens","year":"2025","journal-title":"Diabetes Technol Ther"},{"key":"B20","doi-asserted-by":"publisher","first-page":"e70202","DOI":"10.7759\/cureus.70202","article-title":"Latent autoimmune diabetes in a young female: A case report","volume":"16","author":"Pampapathi","year":"2024","journal-title":"Cureus"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1297\/cpe.2024-0083","article-title":"A case of latent autoimmune diabetes in the young positive for zinc transporter 8 antibody with type 2 diabetes characteristics","volume":"34","author":"Matsuda","year":"2025","journal-title":"Clin Pediatr Endocrinol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1297\/cpe.2024-0039","article-title":"Clinical Pediatric Endocrinology Case Report Trends in endogenous insulin secretion capacity and anti-islet autoantibody titers in two childhood-onset slowly progressive insulin-dependent diabetes mellitus cases","volume":"33","author":"Kanno","year":"2024"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2026.1833794\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T04:24:09Z","timestamp":1782793449000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2026.1833794\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,30]]},"references-count":22,"alternative-id":["10.3389\/fendo.2026.1833794"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2026.1833794","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,30]]},"article-number":"1833794"}}